MALMÖ, SE / ACCESS Newswire / November 15, 2025 / Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Orviglance® for review. The FDA has set an action date of 3 July 2026 under the Prescription Drug User Fee Act (PDUFA).

The FDA has confirmed through their ‘day 74 letter' their acceptance of the NDA filing for Orviglance and continuation of the review aiming for a decision by 3 July 2026 as the PDUFA date.

"This milestone represents yet another significant step towards our goal of making Orviglance available to cancer patients with impaired kidney function. We look forward to continuing to work with the FDA throughout the review process," said Magnus Corfitzen, CEO of Ascelia Pharma. "The FDA filing acceptance is also important for our discussions with potential commercialization partners".

The NDA submission is based on the successful completion of the development program, which includes nine clinical studies with consistent positive efficacy and safety results. In the Phase 3 study, SPARKLE, Orviglance significantly improved visualization of focal liver lesions in patients with impaired kidney function, meeting the primary endpoint with statistical significance (<0.001).< p>

Orviglance has been granted an Orphan Drug Designation by the FDA for use as a contrast agent for liver MRI in patients with severely impaired kidney function. These patients have the highest risk of developing the serious and potentially fatal condition Nephrogenic Systemic Fibrosis (NSF) after exposure to the gadolinium-based contrast agents normally used today. Regulatory bodies have issued warnings for the use of these agents in this vulnerable patient population. Orviglance aims to give patients with impaired kidney function access to safe and effective liver imaging. The unmet need for these patients represents a global annual addressable market potential of USD 800 million.

Contacts

Magnus Corfitzen, CEO
Email: [email protected]
Tel: +46 735 179 118

Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)
Email: [email protected]
Tel: +46 735 179 116

This information was submitted for publication, through the agency of the contact persons set out above.

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates - Orviglance and Oncoral - in development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.

About Orviglance
Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A clinical program of nine studies, including the pivotal global Phase 3 study SPARKLE, has successfully been completed with strong and consistent efficacy and safety results. The New Drug Application (NDA) has been submitted to the FDA.

SOURCE: Ascelia Pharma



View the original
on ACCESS Newswire


Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]